衰老细胞溶解药物靶向肺泡上皮细胞功能并减轻实验性肺纤维化
特发性肺纤维化(IPF)发病率随年龄增加,细胞衰老被认为是致病驱动因素。该研究在实验性和人类肺纤维化组织及原代细胞中发现肺泡上皮细胞P16、P21表达及衰老相关β-半乳糖苷酶活性增加。纤维化小鼠ATII细胞分泌更多衰老相关分泌表型(SASP)因子,药物清除衰老细胞可减少SASP因子和细胞外基质标志物,同时增加肺泡上皮标志物,提示衰老细胞溶解药物可能成为IPF治疗选择。
要点
- 肺纤维化中肺泡上皮细胞呈现衰老特征,P16、P21及SA-β-gal活性增加
- 纤维化ATII细胞分泌SASP因子增多,参与纤维化发展
- 衰老细胞溶解药物可减少SASP和ECM标志物,增加上皮标志物
核心结论
- 肺泡上皮细胞衰老参与肺纤维化发展,衰老细胞溶解药物可能是IPF的可行治疗选择。
研究设计与样本
- 研究采用实验性及人类肺纤维化组织和原代细胞,结合体外和离体三维肺组织培养进行分析。
主要发现
- 在实验性和人类肺纤维化组织及原代细胞中,肺上皮细胞P16和P21表达及衰老相关β-半乳糖苷酶活性增加。
- 原代纤维化小鼠肺泡上皮II型(ATII)细胞在体外分泌更多SASP因子,经定量PCR、质谱和ELISA分析证实。
- 通过诱导纤维化ATII细胞或离体三维肺组织培养中衰老细胞凋亡进行药理清除,可减少SASP因子和细胞外基质标志物,同时增加肺泡上皮标志物。
临床怎么用
- 衰老细胞溶解药物可能通过清除衰老肺泡上皮细胞减少SASP和ECM,为IPF治疗提供新思路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with poor prognosis and limited therapeutic options. The incidence of IPF increases with age, and ageing-related mechanisms such as cellular senescence have been proposed as pathogenic drivers. The lung alveolar epithelium represents a major site of tissue injury in IPF and senescence of this cell population is probably detrimental to lung repair. However, the potential pathomechanisms of alveolar epithelial cell senescence and the impact of senolytic drugs on senescent lung cells and fibrosis remain unknown. Here we demonstrate that lung epithelial cells exhibit increased P16 and P21 expression as well as senescence-associated β-galactosidase activity in experimental and human lung fibrosis tissue and primary cells.Primary fibrotic mouse alveolar epithelial type (AT)II cells secreted increased amounts of senescence-associated secretory phenotype (SASP) factors in vitro, as analysed using quantitative PCR, mass spectrometry and ELISA. Importantly, pharmacological clearance of senescent cells by induction of apoptosis in fibrotic ATII cells or ex vivo three-dimensional lung tissue cultures reduced SASP factors and extracellular matrix markers, while increasing alveolar epithelial markers.These data indicate that alveolar epithelial cell senescence contributes to lung fibrosis development and that senolytic drugs may be a viable therapeutic option for IPF.
引用
- Lehmann M, Korfei M, Mutze K, et al. Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo. Eur Respir J. 2017. PMID: 28775044. doi:10.1183/13993003.02367-2016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。